Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

Blankenship, J C; Hellkamp, A S; Aguirre, F V; Demko, S L; Topol, E J; Califf, R M

Blankenship, J C; Hellkamp, A S; Aguirre, F V; Demko, S L; Topol, E J; Califf, R M.

Affiliation

Blankenship JC; Geisinger Medical Center, Danville, Pennsylvania 17822, USA.

Am J Cardiol ; 81(1): 36-40, 1998 Jan 01.

Article in En | MEDLINE | ID: mdl-9462603

Subject(s)

Angioplasty, Balloon, Coronary/methods; Antibodies, Monoclonal/adverse effects; Catheters, Indwelling/adverse effects; Hemorrhage/etiology; Immunoglobulin Fab Fragments/adverse effects; Platelet Aggregation Inhibitors/adverse effects; Abciximab; Female; Hematocrit; Hemorrhage/blood; Humans; Incidence; Infusions, Intravenous; Injections, Intravenous; Length of Stay; Logistic Models; Male; Prospective Studies; Risk Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin Fab Fragments / Platelet Aggregation Inhibitors / Catheters, Indwelling / Angioplasty, Balloon, Coronary / Hemorrhage / Antibodies, Monoclonal Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Am J Cardiol Year: 1998 Document type: Article

Search on Google

XML

PubMed Links